Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Fibrocystic Breast Diagnostics and Treatment Market, by Type
6.1 Introduction
6.2 Diagnosis
6.2.1 Mammogram
Market Estimates & Forecast, by Region, 2023–2030
Market Estimates & Forecast, by Country, 2023–2030
6.2.2 Breast biopsy
Market Estimates & Forecast, by Region, 2023–2030
Market Estimates & Forecast, by Country, 2023–2030
6.3 Treatment
6.3.1 Medications
6.3.1.1 Acetaminophen
Market Estimates & Forecast, by Region, 2023–2030
Market Estimates & Forecast, by Country, 2023–2030
6.3.1.2 Nonsteroidal anti-inflammatory drugs
Market Estimates & Forecast, by Region, 2023–2030
Market Estimates & Forecast, by Country, 2023–2030
6.3.2 Fine-needle aspiration
Market Estimates & Forecast, by Region, 2023–2030
Market Estimates & Forecast, by Country, 2023–2030
6.3.3 Surgical excision
Market Estimates & Forecast, by Region, 2023–2030
Market Estimates & Forecast, by Country, 2023–2030
6.3.4 Oral contraceptives
Market Estimates & Forecast, by Region, 2023–2030
Market Estimates & Forecast, by Country, 2023–2030
Chapter 7. Global Fibrocystic Breast Diagnostics and Treatment Market, by End-Users
7.1 Introduction
7.2 Hospitals
Market Estimates & Forecast, by Region, 2023–2030
Market Estimates & Forecast, by Country, 2023–2030
7.3 Clinics
Market Estimates & Forecast, by Region, 2023–2030
Market Estimates & Forecast, by Country, 2023–2030
7.4 Ambulatory Surgery Centers
Market Estimates & Forecast, by Region, 2023–2030
Market Estimates & Forecast, by Country, 2023–2030
7.5 Others
Market Estimates & Forecast, by Region, 2023–2030
Market Estimates & Forecast, by Country, 2023–2030
Chapter 8. Global Fibrocystic Breast Diagnostics and Treatment Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 US
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 UK
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia-Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia-Pacific
8.5 Middle East & Africa
8.5.1 Middle East
8.5.2 Africa
Chapter 9. Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
Chapter 10. Company Profiles
10.1 Argon Medical Devices
10.1.1 Company Overview
10.1.2 Type Overview
10.1.3 Financials Overview
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Boston Scientific
10.2.1 Company Overview
10.2.2 Type Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 CareFusion Corporation (Acquired by Becton, Dickinson and Company)
10.3.1 Company Overview
10.3.2 Type Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 C. R. Bard, Inc.
10.4.1 Company Overview
10.4.2 Technology/Business Segment Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 Cook Medical
10.5.1 Company Overview
10.5.2 Type Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Devicor Medical Products Inc.
10.6.1 Company Overview
10.6.2 Type Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 Gallini Medical Devices
10.7.1 Overview
10.7.2 Type Overview
10.7.3 Financial Overview
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Hologic, Inc.
10.8.1 Overview
10.8.2 Type/ Technology Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.7 INRAD, Inc.
10.7.1 Overview
10.7.2 Type Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Merck & Co., Inc.
10.8.1 Overview
10.8.2 Type Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.10 Pfizer Inc.
10.10.1 Overview
10.10.2 Type Overview
10.10.3 Financials
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.10 Teva Pharmaceutical Industries Ltd
10.10.1 Overview
10.10.2 Type Overview
10.10.3 Financials
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.13 Bayer AG
10.13.1 Overview
10.13.2 Type Overview
10.13.3 Financials
10.13.4 Key Developments
10.13.5 SWOT Analysis
10.14 Allergan plc.
10.14.1 Overview
10.14.2 Type Overview
10.14.3 Financials
10.14.4 Key Developments
10.14.5 SWOT Analysis
Chapter 11 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO’s Viewpoint
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch
11.3 Predictions for the Fibrocystic Breast Diagnostics and Treatment Industry
Chapter 12. Appendix
LIST OF TABLES
Table 1 Global Fibrocystic Breast Diagnostics and Treatment Market Synopsis, 2023–2030
Table 2 Global Fibrocystic Breast Diagnostics and Treatment Market Estimates and Forecast, 2023–2030 (USD Million)
Table 3 Global Fibrocystic Breast Diagnostics and Treatment Market, by Region, 2023–2030 (USD Million)
Table 4 Global Fibrocystic Breast Diagnostics and Treatment Market, by Type, 2023–2030 (USD Million)
Table 5 Global Fibrocystic Breast Diagnostics and Treatment Market, by End-users, 2023–2030 (USD Million)
Table 6 North America: Fibrocystic Breast Diagnostics and Treatment, by Type, 2023–2030 (USD
Million)
Table 7 North America: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2023–2030 (USD Million)
Table 8 US: Fibrocystic Breast Diagnostics and Treatment, by Type, 2023–2030 (USD Million)
Table 9 US: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2023–2030 (USD Million)
Table 10 Canada: Fibrocystic Breast Diagnostics and Treatment, by Type, 2023–2030 (USD Million)
Table 11 Canada: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2023–2030 (USD Million)
Table 12 South America: Fibrocystic Breast Diagnostics and Treatment, by Type, 2023–2030 (USD
Million)
Table 13 South America: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2023–2030 (USD Million)
Table 14 Europe: Fibrocystic Breast Diagnostics and Treatment, by Type, 2023–2030 (USD Million)
Table 15 Europe: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2023–2030 (USD Million)
Table 16 Western Europe: Absorbable Surgical Sutures, by Type, 2023–2030 (USD
Million)
Table 17 Western Europe: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2023–2030 (USD Million)
Table 18 Eastern Europe: Fibrocystic Breast Diagnostics and Treatment, by Type, 2023–2030 (USD
Million)
Table 19 Eastern Europe: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2023–2030 (USD Million)
Table 20 Asia-Pacific: Fibrocystic Breast Diagnostics and Treatment, by Type, 2023–2030 (USD
Million)
Table 21 Asia-Pacific: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2023–2030 (USD Million)
Table 22 Middle East & Africa: Fibrocystic Breast Diagnostics and Treatment, by Type, 2023–2030
(USD Million)
Table 23 Middle East & Africa: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2023–2030 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for the Global Fibrocystic Breast Diagnostics and Treatment Market
Figure 3 Market Dynamics for
the Global Fibrocystic Breast Diagnostics and Treatment Market
Global Fibrocystic Breast Diagnostics and Treatment Market
Figure 4 Global Fibrocystic Breast Diagnostics and Treatment Market Share, by Type, 2023
Figure 5 Global Fibrocystic Breast Diagnostics and Treatment Market, by End-users, 2023–2030 (USD Million)
Figure 6 Global Fibrocystic Breast Diagnostics and Treatment Market Share, by Region, 2023
Figure 7 North America: Fibrocystic Breast Diagnostics and Treatment Share, by Country, 2023
Figure 8 Europe: Fibrocystic Breast Diagnostics and Treatment Share, by Country, 2023
Figure 9 Asia-Pacific: Fibrocystic Breast Diagnostics and Treatment Share, by Country, 2023
Figure 10 Middle East & Africa: Fibrocystic Breast Diagnostics and Treatment Share, by Country, 2023
Figure 11 Global Fibrocystic Breast Diagnostics and Treatment Market: Company Share Analysis, 2023 (%)
Figure 12 Argon Medical Devices: Key Financials
Figure 13 Argon Medical Devices: Segmental Revenue
Figure 14 Argon Medical Devices: Geographical Revenue
Figure 15 Boston Scientific: Key Financials
Figure 16 Boston Scientific: Segmental Revenue
Figure 17 B Boston Scientific: Geographical Revenue
Figure 18 CareFusion Corporation (Acquired by Becton, Dickinson and Company): Key Financials
Figure 19 CareFusion Corporation (Acquired by Becton, Dickinson and Company): Segmental Revenue
Figure 20 CareFusion Corporation (Acquired by Becton, Dickinson and Company): Geographical Revenue
Figure 21 C. R. Bard, Inc.: Key Financials
Figure 22 C. R. Bard, Inc: Segmental Revenue
Figure 23 C. R. Bard, Inc.: Geographical Revenue
Figure 24 Cook Medical: Key Financials
Figure 25 Cook Medical: Segmental Revenue
Figure 26 Cook Medical: Geographical Revenue
Figure 27 Devicor Medical Products Inc.: Key Financials
Figure 28 Devicor Medical Products Inc.: Segmental Revenue
Figure 29 Devicor Medical Products Inc.: Geographical Revenue
Figure 30 Gallini Medical Devices: Key Financials
Figure 31 Gallini Medical Devices: Segmental Revenue
Figure 32 Gallini Medical Devices: Geographical Revenue
Figure 33 Hologic, Inc.: Key Financials
Figure 34 Hologic, Inc.: Segmental Revenue
Figure 35 Hologic, Inc.: Geographical Revenue
Figure 36 INRAD, Inc.: Key Financials
Figure 37 INRAD, Inc.: Segmental Revenue
Figure 38 INRAD, Inc.: Geographical Revenue
Figure 39 Merck & Co., Inc.: Key Financials
Figure 40 Merck & Co., Inc.: Segmental Revenue
Figure 41 Merck & Co., Inc.: Geographical Revenue
Figure 42 Pfizer Inc.: Key Financials
Figure 43 Pfizer Inc.: Segmental Revenue
Figure 44 Pfizer Inc.: Geographical Revenue
Figure 45 Teva Pharmaceutical Industries Ltd: Key Financials
Figure 46 Teva Pharmaceutical Industries Ltd: Segmental Revenue
Figure 47 Teva Pharmaceutical Industries Ltd: Geographical Revenue
Figure 48 Bayer AG: Key Financials
Figure 49 Bayer AG: Segmental Revenue
Figure 50 Bayer AG: Geographical Revenue
Figure 51 Allergan plc.: Key Financials
Figure 52 Allergan plc.: Segmental Revenue
Figure 53 Allergan plc.: Geographical Revenue
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
